Objective: Determine markers of disease progression in SS using a longitudinal patient database and proteomics analysis of saliva.
Method: In the present study patient’s data (such as ultrasound scores and salivary flow rates) were retrieved from their records.
Parotid saliva samples were collected from patients (including those grouped as diseased controls, possible SS, SS with or without another autoimmune disease, SS at high risk of developing lymphoma, SS with confirmed lymphoma) attending Oral Medicine clinics.
Parotid saliva samples (healthy control, SS, SS at risk of developing lymphoma) were sent for proteomic analysis using SDSPAGE, trypsin digestion and LC-MS/MS.
Result: So far patient (n=319) data has been collected at 5 and 10 year timepoints. Proteomics of saliva has revealed that a number of proteins were overexpressed in SS compared to control saliva and in saliva from SS at risk of lymphoma compared to SS and control.
Conclusion: It is concluded that a number of potential protein biomarkers of SS and SS at risk of lymphoma are present in parotid saliva.